These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25530180)

  • 1. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
    Bellizzi A; Greco MR; Rubino R; Paradiso A; Forciniti S; Zeeberg K; Cardone RA; Reshkin SJ
    Int J Oncol; 2015 Mar; 46(3):1214-24. PubMed ID: 25530180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel NHERF1 Mutation in Human Breast Cancer Inactivates Inhibition by NHERF1 Protein in EGFR Signaling.
    DU G; Hao C; Gu Y; Wang Z; Jiang WG; He J; Cheng S
    Anticancer Res; 2016 Mar; 36(3):1165-73. PubMed ID: 26977012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
    Yi YW; You K; Bae EJ; Kwak SJ; Seong YS; Bae I
    Int J Oncol; 2015 Jul; 47(1):122-32. PubMed ID: 25955731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
    Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
    Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
    Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
    Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
    Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.
    Widatalla SE; Korolkova OY; Whalen DS; Goodwin JS; Williams KP; Ochieng J; Sakwe AM
    Carcinogenesis; 2019 Aug; 40(8):998-1009. PubMed ID: 30590459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
    Jones HE; Goddard L; Gee JM; Hiscox S; Rubini M; Barrow D; Knowlden JM; Williams S; Wakeling AE; Nicholson RI
    Endocr Relat Cancer; 2004 Dec; 11(4):793-814. PubMed ID: 15613453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.